The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2019 | KCRD induction for NDMM: Myeloma XI trial analysis by molecular risk
Karthik Ramasamy, MBBS, FRCP, FRCPath, PhD, of the Oxford University Hospitals NHS Foundation Trust, Oxford, UK, gives us an update on the analysis of the UK Myeloma XI trial (NCT01554852) by molecular risk from the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands. This trial investigated the efficacy of the quadruplet induction regimen of carfilzomib, cyclophosphamide, lenalidomide and dexamethasone for newly diagnosed multiple myeloma patients.
